Corwin covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Zevra Therapeutics, and Poseida Therapeutics. According to TipRanks, Corwin has an average return of 4.1% and a 50.79% ...

PTC Therapeutics (NASDAQ:PTCT) has received FDA approval for its gene replacement therapy Kebilidi for the treatment of ...

PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...

It's the most popular auto-racing event in the world - but it has taken 30 years for some enthusiasts to notice a hidden detail in the old Formula 1 logo. F1 started in 1950, originating from the ...

PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...

PTC earlier this month reported its fiscal year 2022 financials. For the year, which ended September 30, the company reported revenue of $1.93 billion, up 7 percent year over year. The company is ...

This collaboration will integrate Configit's Configuration Lifecycle Management (CLM) solutions with PTC's Product Lifecycle Management (PLM) systems, offering a comprehensive and cohesive ...

At the start of the year, the company said it expected to make as much as $1 billion in revenue ... 2024 Future of ...

Integration of CLM and PLM enables a streamlined approach to configuration management, leading to faster time to market and more satisfied customers COPENHAGEN, Denmark, Nov. 1, 2024 /PRNewswire/ ...